Are symptoms of BOO and OABS relieved more effectively by doxazosin plus tolterodine than by doxazosin alone?
Jean Jacques Wyndaele
Correspondence Department of Urology, University Hospital of Antwerp, Wilrijkstraat 10, B-2650 Edegem, Belgium
Email Jean-Jacques.Wyndaele@uza.be
This article has no abstract so we have provided the first paragraph of the full text.
There are data indicating that many men with BOO also have detrusor overactivity (DOA). Symptoms related to both conditions can be similar, and distinguishing between the two can be difficult on the basis of clinical presentation alone. Lee et al., in their study of men with symptomatic BOO, showed that doxazosin—a nonspecific long-acting alpha1-adrenergic receptor (AR) antagonist—improves IPSS score by at least three points, mainly in those without concomitant DOA. When tolterodine was added to the treatment regimen of those in whom doxazosin was not effective, 6 out of 16 (38%) improved. Adverse effects were infrequent. The combination of doxazosin and tolterodine might be proposed as a second therapeutic step in men with BOO who do not respond to alpha blockers.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
A role for nitric oxide synthase in urinary ?urge syndrome?Nature Medicine News and Views (01 May 1997)